Search Videos and More
Diagnosis Of Rare Cancer Led To Lifesaving Surgery and Access to Clinical Trial Treatment at UT Southwestern
With the expertise of Jayanthi Lea, M.D., a patient with low-grade serous ovarian carcinoma is now in remission.Shorter, safer protocol effectively treats triple-negative breast cancer
Adding radiation at start of treatment regimen produced results similar to current standard of care with fewer toxic side effectsUTSW scientists identify cancer-suppressing genetic mutation
Findings could eventually lead to improved immunotherapies for melanoma, other cancersHIPEC and Cytoreductive Surgery Combination Shows Promise
UT Southwestern Harold C. Simmons Comprehensive Cancer Center is the first medical center in North Texas to offer a comprehensive multidisciplinary approach to treat certain advanced cancers that spread in the belly cavityRepurposed drug has promising efficacy in non-small cell lung cancer
UTSW-led clinical trial suggests broader use for selinexor in cancers with KRAS mutationsFuture of Thoracic Surgery
Inderpal Sarkaria, M.D., Chief of the Division of Thoracic Surgery, shares his optimism for the future of Thoracic Surgery at UT Southwestern.Director of Simmons Cancer Center, UTSW Pharmacology Chair elected to the National Academy of Medicine
Carlos L. Arteaga, M.D., and David Mangelsdorf, Ph.D., are UTSW’s 23rd and 24th members of the NAM, the most of any institution in TexasLatino enclaves in U.S. have less accessible health care
Study led by UTSW researcher describes socioeconomic challenges in culturally distinct neighborhoods for fastest-growing ethnic groupUT Southwestern biochemist Zhijian ‘James’ Chen, Ph.D., earns prestigious Lasker Award
Dr. Chen’s discovery of cGAS, which triggers innate immunity, also honored with Germany’s top scientific prizePathway tied to cancer-driving genome alterations identified
Understanding how chromosome shattering occurs could lead to strategies to overcome therapy resistance, UTSW study showsWidespread disparities exist in treating advanced cancers
Likelihood of patients receiving FDA-approved immunotherapies for late-stage kidney and bladder cancers linked to race, socioeconomic factors, facility typeBasic Research: R01s – Drs. Todd Aguilera & You Zhang
Doctor Spotlights